LFB USA

LFB USA is the North American subsidiary of the LFB Group, a global biopharmaceutical company specializing in the development and manufacture of therapeutic proteins. The company is a pioneer in transgenic technology, utilizing its proprietary rPRO platform to produce complex recombinant proteins in the milk of genetically engineered animals. Its lead product, ATryn, was the first transgenically produced protein to receive FDA approval, indicated for the prevention of thromboembolic events in patients with hereditary antithrombin deficiency. LFB USA operates specialized manufacturing facilities in Massachusetts and focuses on addressing unmet medical needs in hemostasis, immunology, and intensive care. The company provides both proprietary drug development and contract manufacturing services for complex biologics.